Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 287 entries
Sorted by: Best Match Show Resources per page
Erratum to: Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells.

Breast cancer research and treatment

Bonofiglio D, Gabriele S, Aquila S, Qi H, Belmonte M, Catalano S, Andò S.
PMID: 28822120
Breast Cancer Res Treat. 2017 Nov;166(1):325-326. doi: 10.1007/s10549-017-4456-5.

No abstract available.

Cite
Bonofiglio D, Gabriele S, Aquila S, et al. Erratum to: Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells. Breast Cancer Res Treat. 2017;166(1):325-326doi: 10.1007/s10549-017-4456-5.
Bonofiglio, D., Gabriele, S., Aquila, S., Qi, H., Belmonte, M., Catalano, S., & Andò, S. (2017). Erratum to: Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells. Breast cancer research and treatment, 166(1), 325-326. https://doi.org/10.1007/s10549-017-4456-5
Bonofiglio, Daniela, et al. "Erratum to: Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells." Breast cancer research and treatment vol. 166,1 (2017): 325-326. doi: https://doi.org/10.1007/s10549-017-4456-5
Bonofiglio D, Gabriele S, Aquila S, Qi H, Belmonte M, Catalano S, Andò S. Erratum to: Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells. Breast Cancer Res Treat. 2017 Nov;166(1):325-326. doi: 10.1007/s10549-017-4456-5. PMID: 28822120.
Copy Download .nbib Format: NLM
Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.

Breast cancer research and treatment

Asaduzzaman M, Constantinou S, Min H, Gallon J, Lin ML, Singh P, Raguz S, Ali S, Shousha S, Charles Coombes R, Lam EW, Hu Y, Yagüe E.
PMID: 29305809
Breast Cancer Res Treat. 2018 Jan;167(2):605-606. doi: 10.1007/s10549-017-4633-6.

In the original publication, Fig. 1 depicting the blot for EP300 in CAL51 cells (Fig. 1c) was unintentionally duplicated with that from MDA-MB-231 cells (Fig. 1d). The new figure given in this erratum depicts the correct EP300 blot in...

Cite
Asaduzzaman M, Constantinou S, Min H, et al. Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. Breast Cancer Res Treat. 2018;167(2):605-606doi: 10.1007/s10549-017-4633-6.
Asaduzzaman, M., Constantinou, S., Min, H., Gallon, J., Lin, M. L., Singh, P., Raguz, S., Ali, S., Shousha, S., Charles Coombes, R., Lam, E. W., Hu, Y., & Yagüe, E. (2018). Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. Breast cancer research and treatment, 167(2), 605-606. https://doi.org/10.1007/s10549-017-4633-6
Asaduzzaman, Muhammad, et al. "Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer." Breast cancer research and treatment vol. 167,2 (2018): 605-606. doi: https://doi.org/10.1007/s10549-017-4633-6
Asaduzzaman M, Constantinou S, Min H, Gallon J, Lin ML, Singh P, Raguz S, Ali S, Shousha S, Charles Coombes R, Lam EW, Hu Y, Yagüe E. Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. Breast Cancer Res Treat. 2018 Jan;167(2):605-606. doi: 10.1007/s10549-017-4633-6. PMID: 29305809; PMCID: PMC6828501.
Copy Download .nbib Format: NLM
Erratum to: Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis.

Breast cancer research and treatment

Shaitelman SF, Chiang YJ, Griffin KD, De Snyder SM, Smith BD, Schaverien MV, Woodward WA, Cormier JN.
PMID: 28185145
Breast Cancer Res Treat. 2017 Apr;162(2):217. doi: 10.1007/s10549-017-4116-9.

No abstract available.

Cite
Shaitelman SF, Chiang YJ, Griffin KD, et al. Erratum to: Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast Cancer Res Treat. 2017;162(2):217doi: 10.1007/s10549-017-4116-9.
Shaitelman, S. F., Chiang, Y. J., Griffin, K. D., De Snyder, S. M., Smith, B. D., Schaverien, M. V., Woodward, W. A., & Cormier, J. N. (2017). Erratum to: Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast cancer research and treatment, 162(2), 217. https://doi.org/10.1007/s10549-017-4116-9
Shaitelman, Simona F, et al. "Erratum to: Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis." Breast cancer research and treatment vol. 162,2 (2017): 217. doi: https://doi.org/10.1007/s10549-017-4116-9
Shaitelman SF, Chiang YJ, Griffin KD, De Snyder SM, Smith BD, Schaverien MV, Woodward WA, Cormier JN. Erratum to: Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast Cancer Res Treat. 2017 Apr;162(2):217. doi: 10.1007/s10549-017-4116-9. PMID: 28185145.
Copy Download .nbib Format: NLM
Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.

Breast cancer research and treatment

Leopold C, Wagner AK, Zhang F, Lu CY, Earle C, Nekhlyudov L, Ross-Degnan D, Wharam JF.
PMID: 27696008
Breast Cancer Res Treat. 2016 Nov;160(2):385. doi: 10.1007/s10549-016-3988-4.

No abstract available.

Cite
Leopold C, Wagner AK, Zhang F, et al. Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. Breast Cancer Res Treat. 2016;160(2):385doi: 10.1007/s10549-016-3988-4.
Leopold, C., Wagner, A. K., Zhang, F., Lu, C. Y., Earle, C., Nekhlyudov, L., Ross-Degnan, D., & Wharam, J. F. (2016). Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. Breast cancer research and treatment, 160(2), 385. https://doi.org/10.1007/s10549-016-3988-4
Leopold, Christine, et al. "Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer." Breast cancer research and treatment vol. 160,2 (2016): 385. doi: https://doi.org/10.1007/s10549-016-3988-4
Leopold C, Wagner AK, Zhang F, Lu CY, Earle C, Nekhlyudov L, Ross-Degnan D, Wharam JF. Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. Breast Cancer Res Treat. 2016 Nov;160(2):385. doi: 10.1007/s10549-016-3988-4. PMID: 27696008; PMCID: PMC6625315.
Copy Download .nbib Format: NLM
Erratum to: Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.

Breast cancer research and treatment

Gil EY, Jo UH, Lee HJ, Kang J, Seo JH, Lee ES, Kim YH, Kim I, Phan-Lai V, Disis ML, Park KH.
PMID: 26888722
Breast Cancer Res Treat. 2016 Feb;155(3):617-8. doi: 10.1007/s10549-016-3715-1.

No abstract available.

Cite
Gil EY, Jo UH, Lee HJ, et al. Erratum to: Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice. Breast Cancer Res Treat. 2016;155(3):617-8doi: 10.1007/s10549-016-3715-1.
Gil, E. Y., Jo, U. H., Lee, H. J., Kang, J., Seo, J. H., Lee, E. S., Kim, Y. H., Kim, I., Phan-Lai, V., Disis, M. L., & Park, K. H. (2016). Erratum to: Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice. Breast cancer research and treatment, 155(3), 617-8. https://doi.org/10.1007/s10549-016-3715-1
Gil, Eun-Young, et al. "Erratum to: Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice." Breast cancer research and treatment vol. 155,3 (2016): 617-8. doi: https://doi.org/10.1007/s10549-016-3715-1
Gil EY, Jo UH, Lee HJ, Kang J, Seo JH, Lee ES, Kim YH, Kim I, Phan-Lai V, Disis ML, Park KH. Erratum to: Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice. Breast Cancer Res Treat. 2016 Feb;155(3):617-8. doi: 10.1007/s10549-016-3715-1. PMID: 26888722.
Copy Download .nbib Format: NLM
UK Interdisciplinary Breast Cancer Symposium 2020.

Breast cancer research and treatment

[No authors listed]
PMID: 32026211
Breast Cancer Res Treat. 2020 Apr;180(2):527-596. doi: 10.1007/s10549-019-05514-3.

No abstract available.

Cite
UK Interdisciplinary Breast Cancer Symposium 2020. Breast Cancer Res Treat. 2020;180(2):527-596doi: 10.1007/s10549-019-05514-3.
(2020). UK Interdisciplinary Breast Cancer Symposium 2020. Breast cancer research and treatment, 180(2), 527-596. https://doi.org/10.1007/s10549-019-05514-3
"UK Interdisciplinary Breast Cancer Symposium 2020." Breast cancer research and treatment vol. 180,2 (2020): 527-596. doi: https://doi.org/10.1007/s10549-019-05514-3
UK Interdisciplinary Breast Cancer Symposium 2020. Breast Cancer Res Treat. 2020 Apr;180(2):527-596. doi: 10.1007/s10549-019-05514-3. PMID: 32026211.
Copy Download .nbib Format: NLM
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.

Breast cancer research and treatment

Turner N, Dent RA, O'Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, Saji S, Bondarenko I, Nowecki Z, Lian Q, Reilly SJ, Hinton H, Wongchenko MJ, Kovic B, Mani A, Oliveira M.
PMID: 34860318
Breast Cancer Res Treat. 2021 Dec 03; doi: 10.1007/s10549-021-06450-x. Epub 2021 Dec 03.

PURPOSE: PI3K/AKT pathway alterations are frequent in hormone receptor-positive (HR+) breast cancers. IPATunity130 Cohort B investigated ipatasertib-paclitaxel in PI3K pathway-mutant HR+ unresectable locally advanced/metastatic breast cancer (aBC).METHODS: Cohort B of the randomized, double-blind, placebo-controlled, phase 3 IPATunity130 trial enrolled...

Cite
Turner N, Dent RA, O'Shaughnessy J, et al. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat. 2021;doi: 10.1007/s10549-021-06450-x.
Turner, N., Dent, R. A., O'Shaughnessy, J., Kim, S. B., Isakoff, S. J., Barrios, C., Saji, S., Bondarenko, I., Nowecki, Z., Lian, Q., Reilly, S. J., Hinton, H., Wongchenko, M. J., Kovic, B., Mani, A., & Oliveira, M. (2021). Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast cancer research and treatment, . https://doi.org/10.1007/s10549-021-06450-x
Turner, Nicholas, et al. "Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial." Breast cancer research and treatment vol. (2021). doi: https://doi.org/10.1007/s10549-021-06450-x
Turner N, Dent RA, O'Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, Saji S, Bondarenko I, Nowecki Z, Lian Q, Reilly SJ, Hinton H, Wongchenko MJ, Kovic B, Mani A, Oliveira M. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat. 2021 Dec 03; doi: 10.1007/s10549-021-06450-x. Epub 2021 Dec 03. PMID: 34860318.
Copy Download .nbib Format: NLM
Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield.

Breast cancer research and treatment

Onega T, Zhu W, Kerlikowske K, Miglioretti DL, Lee CI, Henderson LM, Tosteson ANA, Wernli KJ, diFlorio R, Weaver DL, Buist DSM.
PMID: 34686934
Breast Cancer Res Treat. 2022 Jan;191(1):177-190. doi: 10.1007/s10549-021-06418-x. Epub 2021 Oct 22.

PURPOSE: Preoperative breast MRI is used to evaluate for additional cancer and extent of disease for newly diagnosed breast cancer, yet benefits and harms of preoperative MRI are not well-documented. We examined whether preoperative MRI yields additional biopsy and...

Cite
Onega T, Zhu W, Kerlikowske K, et al. Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield. Breast Cancer Res Treat. 2021;191(1):177-190doi: 10.1007/s10549-021-06418-x.
Onega, T., Zhu, W., Kerlikowske, K., Miglioretti, D. L., Lee, C. I., Henderson, L. M., Tosteson, A. N. A., Wernli, K. J., diFlorio, R., Weaver, D. L., & Buist, D. S. M. (2022). Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield. Breast cancer research and treatment, 191(1), 177-190. https://doi.org/10.1007/s10549-021-06418-x
Onega, Tracy, et al. "Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield." Breast cancer research and treatment vol. 191,1 (2022): 177-190. doi: https://doi.org/10.1007/s10549-021-06418-x
Onega T, Zhu W, Kerlikowske K, Miglioretti DL, Lee CI, Henderson LM, Tosteson ANA, Wernli KJ, diFlorio R, Weaver DL, Buist DSM. Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield. Breast Cancer Res Treat. 2022 Jan;191(1):177-190. doi: 10.1007/s10549-021-06418-x. Epub 2021 Oct 22. PMID: 34686934.
Copy Download .nbib Format: NLM
Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN.

Breast cancer research and treatment

Gold EB, Crawford SL, Leung K, Greendale G, Reeves KW, Joffe H, Avis NE.
PMID: 34694536
Breast Cancer Res Treat. 2022 Jan;191(1):125-135. doi: 10.1007/s10549-021-06425-y. Epub 2021 Oct 25.

PURPOSE: We compared trajectories of vasomotor symptoms (VMS) and their risk factors in women with breast cancer (BrCa) to those of cancer-free controls.METHODS: Data were from 15 nearly annual follow-up visits (1996-2017) of the multi-racial/ethnic cohort of midlife women...

Cite
Gold EB, Crawford SL, Leung K, et al. Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN. Breast Cancer Res Treat. 2021;191(1):125-135doi: 10.1007/s10549-021-06425-y.
Gold, E. B., Crawford, S. L., Leung, K., Greendale, G., Reeves, K. W., Joffe, H., & Avis, N. E. (2022). Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN. Breast cancer research and treatment, 191(1), 125-135. https://doi.org/10.1007/s10549-021-06425-y
Gold, Ellen B, et al. "Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN." Breast cancer research and treatment vol. 191,1 (2022): 125-135. doi: https://doi.org/10.1007/s10549-021-06425-y
Gold EB, Crawford SL, Leung K, Greendale G, Reeves KW, Joffe H, Avis NE. Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN. Breast Cancer Res Treat. 2022 Jan;191(1):125-135. doi: 10.1007/s10549-021-06425-y. Epub 2021 Oct 25. PMID: 34694536.
Copy Download .nbib Format: NLM
Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer.

Breast cancer research and treatment

Cheung YM, Cromwell GE, Tolaney SM, Min L, McDonnell ME.
PMID: 35000092
Breast Cancer Res Treat. 2022 Jan 09; doi: 10.1007/s10549-021-06476-1. Epub 2022 Jan 09.

PURPOSE: Alpelisib is a phosphoinositide-3-kinase inhibitor approved for hormone-receptor-positive, PIK3CA-mutated metastatic breast cancer. However, length of drug exposure, maximum-tolerated dose, and therefore clinical response can vary significantly outside of the trial setting. This study evaluates our center's "real world"...

Cite
Cheung YM, Cromwell GE, Tolaney SM, et al. Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer. Breast Cancer Res Treat. 2022;doi: 10.1007/s10549-021-06476-1.
Cheung, Y. M., Cromwell, G. E., Tolaney, S. M., Min, L., & McDonnell, M. E. (2022). Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer. Breast cancer research and treatment, . https://doi.org/10.1007/s10549-021-06476-1
Cheung, Yee-Ming M, et al. "Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer." Breast cancer research and treatment vol. (2022). doi: https://doi.org/10.1007/s10549-021-06476-1
Cheung YM, Cromwell GE, Tolaney SM, Min L, McDonnell ME. Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer. Breast Cancer Res Treat. 2022 Jan 09; doi: 10.1007/s10549-021-06476-1. Epub 2022 Jan 09. PMID: 35000092.
Copy Download .nbib Format: NLM
Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study.

Breast cancer research and treatment

Sarma M, Perimbeti S, Nasir S, Attwood K, Kapoor A, O'Connor T, Early A, Levine EG, Takabe K, Kalinski P, Ambrosone C, Khoury T, Yao S, Gandhi S.
PMID: 35000093
Breast Cancer Res Treat. 2022 Jan 09; doi: 10.1007/s10549-021-06506-y. Epub 2022 Jan 09.

PURPOSE: To examine the association between race and clinical outcomes (pathological complete response [pCR]; recurrence-free survival [RFS], and overall survival [OS]) in patients diagnosed with triple-negative (TNBC) or HER2-positive breast cancer treated with neoadjuvant chemotherapy (NAC).METHODS: Patients who self-identified...

Cite
Sarma M, Perimbeti S, Nasir S, et al. Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study. Breast Cancer Res Treat. 2022;doi: 10.1007/s10549-021-06506-y.
Sarma, M., Perimbeti, S., Nasir, S., Attwood, K., Kapoor, A., O'Connor, T., Early, A., Levine, E. G., Takabe, K., Kalinski, P., Ambrosone, C., Khoury, T., Yao, S., & Gandhi, S. (2022). Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study. Breast cancer research and treatment, . https://doi.org/10.1007/s10549-021-06506-y
Sarma, Maithreyi, et al. "Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study." Breast cancer research and treatment vol. (2022). doi: https://doi.org/10.1007/s10549-021-06506-y
Sarma M, Perimbeti S, Nasir S, Attwood K, Kapoor A, O'Connor T, Early A, Levine EG, Takabe K, Kalinski P, Ambrosone C, Khoury T, Yao S, Gandhi S. Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study. Breast Cancer Res Treat. 2022 Jan 09; doi: 10.1007/s10549-021-06506-y. Epub 2022 Jan 09. PMID: 35000093.
Copy Download .nbib Format: NLM
IMPARTER, Phase 1 of an intervention to improve patients' understanding of gene expression profiling tests in breast cancer.

Breast cancer research and treatment

Fallowfield LJ, Farewell D, Jones H, May S, Catt S, Starkings R, Jenkins V.
PMID: 34982321
Breast Cancer Res Treat. 2022 Jan 04; doi: 10.1007/s10549-021-06491-2. Epub 2022 Jan 04.

PURPOSE: To compare participants' knowledge about gene expression profiling (GEP) tests and recurrence risks after reading an information leaflet with that following viewing of an information film.METHODS: Using a randomised cross-over design, at time-point one (T1), women aged 45-75...

Cite
Fallowfield LJ, Farewell D, Jones H, et al. IMPARTER, Phase 1 of an intervention to improve patients' understanding of gene expression profiling tests in breast cancer. Breast Cancer Res Treat. 2022;doi: 10.1007/s10549-021-06491-2.
Fallowfield, L. J., Farewell, D., Jones, H., May, S., Catt, S., Starkings, R., & Jenkins, V. (2022). IMPARTER, Phase 1 of an intervention to improve patients' understanding of gene expression profiling tests in breast cancer. Breast cancer research and treatment, . https://doi.org/10.1007/s10549-021-06491-2
Fallowfield, L J, et al. "IMPARTER, Phase 1 of an intervention to improve patients' understanding of gene expression profiling tests in breast cancer." Breast cancer research and treatment vol. (2022). doi: https://doi.org/10.1007/s10549-021-06491-2
Fallowfield LJ, Farewell D, Jones H, May S, Catt S, Starkings R, Jenkins V. IMPARTER, Phase 1 of an intervention to improve patients' understanding of gene expression profiling tests in breast cancer. Breast Cancer Res Treat. 2022 Jan 04; doi: 10.1007/s10549-021-06491-2. Epub 2022 Jan 04. PMID: 34982321; PMCID: PMC8750374.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 287 entries